Cronos Group (TSE:CRON) PT Set at C$4.25 by Canaccord Genuity Group

Cronos Group (TSE:CRON) has been assigned a C$4.25 price objective by equities research analysts at Canaccord Genuity Group in a research report issued on Tuesday,BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price target indicates a potential upside of 17.40% from the company’s previous close.

Cronos Group Trading Down 2.4%

Shares of TSE CRON opened at C$3.62 on Tuesday. Cronos Group has a 12-month low of C$2.27 and a 12-month high of C$4.66. The company has a market cap of C$1.39 billion, a price-to-earnings ratio of 32.91, a price-to-earnings-growth ratio of 0.12 and a beta of 1.13. The company has a current ratio of 24.24, a quick ratio of 24.01 and a debt-to-equity ratio of 0.17. The stock’s 50 day simple moving average is C$3.69 and its 200 day simple moving average is C$3.50.

Cronos Group (TSE:CRON) last issued its quarterly earnings data on Thursday, November 6th. The company reported C$0.07 EPS for the quarter. The firm had revenue of C$50.60 million during the quarter. Cronos Group had a negative return on equity of 4.40% and a negative net margin of 42.65%. Equities research analysts expect that Cronos Group will post -0.26 EPS for the current year.

About Cronos Group

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.